• PDF / 169,595 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 0 Downloads / 169 Views

DOWNLOAD

REPORT

---

1 S

Mycophenolate-mofetil/mycophenolate-sodium Intrauterine death of fetus, spontaneous abortion and contraindicated drug administered: 4 case reports

In a retrospective, one-center study involving 26 pregnant women (aged 23–44 years) who had undergone kidney transplantation between 1987 and December 2018, 4 adult women [exact ages not stated] were described, who experienced intrauterine death of fetus (2 patients) and spontaneous abortion (2 patients) following treatment with mycophenolate mofetil or mycophenolate sodium for immunosuppression during pregnancy [routes and dosages not stated]. Also, the administration of mycophenolate mofetil was considered as a contraindicated drug administration in pregnancy. The pregnant women were receiving mycophenolate mofetil (n=3) or mycophenolate sodium (n=1) for immunosuppression due to a history of kidney transplantation. Subsequently, two of the four women had intrauterine death of fetus secondary to mycophenolate mofetil at 23 weeks and 24 weeks of gestation, respectively. The remaining two women developed spontaneous abortion secondary to mycophenolate mofetil (n=1), and mycophenolate sodium (n=1). Three of the women also had various maternal risk factors, which had contributed to the intrauterine fetal deaths and spontaneous abortion. Treatment with mycophenolate mofetil was considered as a contraindicated drug administration in pregnancy in the three women who received it. Debska-Slizien A, et al. Pregnancy After Kidney Transplantation With Maternal and Pediatric Outcomes: A Single-Center Experience. Transplantation Proceedings 52: 803519715 2430-2435, No. 8, Oct 2020. Available from: URL: http://doi.org/10.1016/j.transproceed.2020.01.122

0114-9954/20/1833-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

Reactions 5 Dec 2020 No. 1833